173 related articles for article (PubMed ID: 30885978)
1. An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1
Xu S; Zhou T; Doh HM; Trinh KR; Catapang A; Lee JT; Braas D; Bayley NA; Yamada RE; Vasuthasawat A; Sasine JP; Timmerman JM; Larson SM; Kim Y; MacLeod AR; Morrison SL; Herschman HR
Cancer Res; 2019 May; 79(10):2748-2760. PubMed ID: 30885978
[TBL] [Abstract][Full Text] [Related]
2. A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers.
Xu S; Herschman HR
Cancer Res; 2019 Dec; 79(23):5907-5914. PubMed ID: 31434645
[TBL] [Abstract][Full Text] [Related]
3. A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers.
Xu S; Catapang A; Braas D; Stiles L; Doh HM; Lee JT; Graeber TG; Damoiseaux R; Shirihai O; Herschman HR
Cancer Metab; 2018; 6():7. PubMed ID: 29988332
[TBL] [Abstract][Full Text] [Related]
4. Hexokinase 2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of tissues of origin.
Xu S; Catapang A; Doh HM; Bayley NA; Lee JT; Braas D; Graeber TG; Herschman HR
J Nucl Med; 2018 Jun; 60(2):212-7. PubMed ID: 29880505
[TBL] [Abstract][Full Text] [Related]
5. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells.
Kudryavtseva AV; Fedorova MS; Zhavoronkov A; Moskalev AA; Zasedatelev AS; Dmitriev AA; Sadritdinova AF; Karpova IY; Nyushko KM; Kalinin DV; Volchenko NN; Melnikova NV; Klimina KM; Sidorov DV; Popov AY; Nasedkina TV; Kaprin AD; Alekseev BY; Krasnov GS; Snezhkina AV
BMC Genet; 2016 Dec; 17(Suppl 3):156. PubMed ID: 28105937
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma.
Ikeda S; Abe F; Matsuda Y; Kitadate A; Takahashi N; Tagawa H
Cancer Sci; 2020 Nov; 111(11):4088-4101. PubMed ID: 32790954
[TBL] [Abstract][Full Text] [Related]
7. ErbB2-upregulated HK1 and HK2 promote breast cancer cell proliferation, migration and invasion.
Ma X; Chen J; Huang B; Fu S; Qu S; Yu R; Zhao Y
Med Oncol; 2023 Apr; 40(5):154. PubMed ID: 37079118
[TBL] [Abstract][Full Text] [Related]
8. The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition.
Tseng PL; Chen CW; Hu KH; Cheng HC; Lin YH; Tsai WH; Cheng TJ; Wu WH; Yeh CW; Lin CC; Tsai HJ; Chang HC; Chuang JH; Shan YS; Chang WT
Oncotarget; 2018 Apr; 9(27):18949-18969. PubMed ID: 29721175
[TBL] [Abstract][Full Text] [Related]
9. Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
Vartanian A; Agnihotri S; Wilson MR; Burrell KE; Tonge PD; Alamsahebpour A; Jalali S; Taccone MS; Mansouri S; Golbourn B; Aldape KD; Zadeh G
Oncotarget; 2016 Oct; 7(43):69518-69535. PubMed ID: 27588472
[TBL] [Abstract][Full Text] [Related]
10. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
[TBL] [Abstract][Full Text] [Related]
11. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme.
Wolf A; Agnihotri S; Munoz D; Guha A
Neurobiol Dis; 2011 Oct; 44(1):84-91. PubMed ID: 21726646
[TBL] [Abstract][Full Text] [Related]
12. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2.
Li W; Zheng M; Wu S; Gao S; Yang M; Li Z; Min Q; Sun W; Chen L; Xiang G; Li H
J Exp Clin Cancer Res; 2017 Apr; 36(1):58. PubMed ID: 28427443
[TBL] [Abstract][Full Text] [Related]
13. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
14. Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin.
Šimčíková D; Gardáš D; Hložková K; Hruda M; Žáček P; Rob L; Heneberg P
Cancer Metab; 2021 Dec; 9(1):41. PubMed ID: 34895333
[TBL] [Abstract][Full Text] [Related]
15. Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth.
Liu Y; Murray-Stewart T; Casero RA; Kagiampakis I; Jin L; Zhang J; Wang H; Che Q; Tong H; Ke J; Jiang F; Wang F; Wan X
Int J Oncol; 2017 Jun; 50(6):2011-2023. PubMed ID: 28498475
[TBL] [Abstract][Full Text] [Related]
16. Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis.
Zheng M; Wu C; Yang K; Yang Y; Liu Y; Gao S; Wang Q; Li C; Chen L; Li H
Pharmacol Res; 2021 Feb; 164():105367. PubMed ID: 33307221
[TBL] [Abstract][Full Text] [Related]
17. Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway.
Wu J; Zhang X; Wang Y; Sun Q; Chen M; Liu S; Zou X
Oncol Rep; 2018 Mar; 39(3):1181-1190. PubMed ID: 29286170
[TBL] [Abstract][Full Text] [Related]
18. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.
Patra KC; Wang Q; Bhaskar PT; Miller L; Wang Z; Wheaton W; Chandel N; Laakso M; Muller WJ; Allen EL; Jha AK; Smolen GA; Clasquin MF; Robey B; Hay N
Cancer Cell; 2013 Aug; 24(2):213-228. PubMed ID: 23911236
[TBL] [Abstract][Full Text] [Related]
19. Spermatogenic cell-specific type 1 hexokinase is the predominant hexokinase in sperm.
Nakamura N; Shibata H; O'Brien DA; Mori C; Eddy EM
Mol Reprod Dev; 2008 Apr; 75(4):632-40. PubMed ID: 17924400
[TBL] [Abstract][Full Text] [Related]
20. Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics.
Garcia SN; Guedes RC; Marques MM
Curr Med Chem; 2019; 26(41):7285-7322. PubMed ID: 30543165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
